Compare AstraZeneca plc (AZN) vs Manchester United PLC (MANU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Manchester United PLC — how do they compare? AstraZeneca plc trades at $157.57 (market cap $248.14B), while Manchester United PLC trades at $22.89 (market cap $3.80B). The key difference: AstraZeneca plc is far larger — about 65.3× Manchester United PLC's market cap, and AstraZeneca plc pays the higher dividend (2.01%). Which is the better fit depends on your goals.
| AZN | MANU | |
|---|---|---|
Market Cap | $248.14B | $3.80B |
Sector | Health | Media |
52-Week High | $209.48 | $23.53 |
52-Week Low | $147.06 | $15.10 |
Enterprise Value | $275.41B | $4.74B |
Dividend Yield | 2.01% | 1.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $161.91, up 0.3% on the day, amid mixed technical signals and strong fundamental performance. The stock exhibits a bearish technical trend with key support at $161 and resistance at $163, while recent earnings consistently beat expectations with Q2 2026 EPS of $2.63 versus $2.50 estimated. Revenue growth has been robust, climbing from $44.4B in 2022 to $58.7B in 2025, with a net income margin of 17.4% in 2025. Recent news centers on potential merger discussions with Bristol Myers Squibb, though reports on August 5, 2026, from Reuters indicate no current talks.
The outlook for AZN is cautiously optimistic, driven by solid profitability and analyst support, but tempered by merger-related volatility and a bearish technical setup. Investment opportunities lie in its high gross margin of 81.88% and positive earnings trajectory, while risks include integration challenges from any future acquisitions and market sensitivity to deal speculation. The stock's valuation at a P/E of 23.76 appears reasonable given its growth profile.
Manchester United (MANU) trades at $21.70, up 0.32% on the day, with a bearish technical signal but improving fundamentals. Recent Q1 2026 earnings beat expectations, though the company remains unprofitable with a net income margin of -2.65%. Key developments include securing land for a new 100,000-seat stadium and Champions League qualification, which may boost future revenue.
The outlook is mixed: operational improvements and stadium plans offer long-term growth potential, but persistent losses, high debt, and weak cash conversion pose risks. Analyst sentiment is cautious with 40% buy ratings. Investors should weigh recovery prospects against financial stability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Manchester United PLC
Manchester United PLC operates a professional football club together with related and ancillary activities. The company manages the soccer team and all affiliated club activities of the Manchester United Football Club, which includes the media network, foundation, fan zone, news, sports features, and team merchandise. Manchester United is based in England. The company has three principal sectors from which most of the revenue is generated, including Commercial, Broadcasting, and Matchday.
Read more on MANU →
